Insurance Benefit Evaluation Committee assesses benefit for ‘Rupapin Tab’ and conditional uninsured for ‘Edarbi Tab’

The Health Insurance Review & Assessment Service Health Insurance Benefit Evaluation Committee held a meeting on the 27^th and assessed propriety for health insurance benefits on 10 companies’ 15 products.

According to the decision result, Takeda Korea’s Edarbi Tab(20, 40 & 80mg), an essential hypertension treatment, was evaluated conditional uninsured benefits. Condition uninsured benefit is g...